|
1）Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448(7153): 561-6
|
|
|
|
2）Soda M, Takada S, Takeuchi K, et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A. 2008; 105(50): 19893-7
|
|
|
|
|
3）Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363(18): 1693-703
|
|
|
|
|
|
4）Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res. 2009; 15(9): 3143-9
|
|
|
|
|
|
5）Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012; 18(3): 382-4
|
|
|
|
|
|
6）Soda M, Isobe K, Inoue A, et al. A Prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancer. Clin Cancer Res. 2012; 18(20): 5682-9
|
|
|
|
|
|
7）Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012; 18(3): 378-81
|
|
|
|
|
|
8）Osoegawa A, Nosaki K, Miyamoto H, et al. Incidentally proven pulmonary “ALKoma”. Intern Med. 2010; 49(6): 603-6
|
|
|
|